Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Herbert J. Zeh, Shikhar Uttam, Alessandro Paniccia, Melissa E. Hogg, Kevin McGrath, Adam Slivka, Vikram C. Gorantla, Rohit Das, Katelyn Smith, Roby Antony Thomas, Asif Khalid, Michael S. Landau, Kenneth E. Fasanella, Natalie Seiser, James F. Pingpank, Harkirat Singh, Nathan Bahary, Patrick Henn, Kenneth K. Lee, Brian K. Theisen, Melanie Ongchin, Savreet Sarkaria, Randall E. Brand, Aatur D. Singhi, Brian A. Boone, Amer H. Zureikat, Susannah G. Ellsworth, N. Paul Ohori, Anil K. Dasyam, Jennifer Chennat, Susan Shyu, John C. Rhee
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND & AIMS: The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current gradi
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Amer H. Zureikat, Takahito Yagi, Kosei Takagi, Yuzo Umeda, Toshiyoshi Fujiwara, M.E. Hogg, Bas Groot Koerkamp, Ryuichi Yoshida
Publikováno v:
World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-7 (2021)
World Journal of Surgical Oncology
World Journal of Surgical Oncology, 19(1):55. BioMed Central Ltd.
World Journal of Surgical Oncology
World Journal of Surgical Oncology, 19(1):55. BioMed Central Ltd.
Background Growing evidence for the advantages of robotic pancreatoduodenectomy (RPD) has been demonstrated internationally. However, there has been no structured training program for RPD in Japan. Herein, we present the surgical training model of RP
Autor:
Brian A. Boone, Kelsey A. Musgrove, Carl Schmidt, Alan A Thomay, Pavan Rao, Britney R. Harris, Melissa E. Hogg, Herbert J. Zeh, Amer H. Zureikat, J. Wallis Marsh
Publikováno v:
J Surg Oncol
Introduction The learning curve associated with robotic pancreatoduodenectomy (RPD) is a hurdle for new programs to achieve optimal results. Since early analysis, robotic training has recently expanded, and the RPD approach has been refined. The purp
Autor:
A. Floortje van Oosten, Michael J. Pflüger, Wenjie Huang, Elizabeth D. Thompson, Vincent P. Groot, Steven Gallinger, Sandra Fischer, Limin Xia, Neil M. Neumann, Nicholas J. Roberts, Richard A. Burkhart, Stefan Heinrich, Alina Hasanain, Claudio Luchini, Jin He, Kim-Vy Nguyen-Ngoc, Bernat Navarro-Serer, Anne Macgregor-Das, Laura D. Wood, Maria A. Trujillo, Gemma Lionheart, Andrew J. Ewald, Peter Chianchiano, Michael Goggins, Amer H. Zureikat, Christopher L. Wolfgang, Randall E. Brand, Yea Ji Jeong, Matthias M. Gaida, Cameron Dowiak, Tammy Ng, Aatur D. Singhi, Danielle Jones, Kohei Fujikura, Bo Huang, Nicola Veronese
Publikováno v:
Cancer Res
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by extensive local invasion and systemic spread. In this study, we employed a three-dimensional organoid model of human pancreatic cancer to characterize the molecular
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Publikováno v:
Journal of the National Comprehensive Cancer Network. 16:1424-1428
Gastrointestinal stromal tumors (GISTs) represent 1% of alimentary tract neoplasms. Up to 90% of GISTs are driven by activating mutations in tyrosine kinase KIT or PDGFRα genes. Imatinib mesylate is a tyrosine kinase inhibitor that has recently been
Autor:
Mohamed A. Adam, Amer H. Zureikat, Stacy J. Kowalsky, Ibrahim Nassour, Alessandro Paniccia, Aatur D. Singhi, Nathan Bahary, Kenneth K.W. Lee, Samer Al Masri
Publikováno v:
Journal of surgical oncologyREFERENCES. 123(1)
BACKGROUND There are limited data on the efficacy of neoadjuvant therapy (NAT) for early-stage distal pancreas adenocarcinoma (PDAC). Previous studies focused on adenocarcinoma of the head of the pancreas or dealt with borderline and locally advanced